Close Menu

Abbott

Bringing testing closer to patients could be helpful, provided enough tests and instruments can be manufactured and distributed.

The ID Now COVID-19 test is the second assay from the company to receive EUA from the FDA, following the same designation issued to the Abbott RealTime SARS CoV-2.

The test will run on the m2000 RealTime molecular system, and the company said it will be shipping 150,000 tests immediately.

A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.

Abbott said the increase in diagnostics revenue was driven by adoption of the company's Alinity family of diagnostic instruments.

Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.

Get the latest news from Illumina, TRC, Diagnomics, Danaher, BioDiscovery and Abbot for the week of 9/13/19

In US influenza testing, providers see growth in placements within hospital emergency departments, physicians' offices, urgent care centers, and retail clinics.

The firm said that its molecular diagnostics sales growth in the quarter was negatively impacted by non-governmental organization purchasing patterns in Africa.

Pages

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.